Cita APA

JL, O., AT, A., AM, C., D, H., M, D. C. G., V, S., . . . E, d. Á. (2015). The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.

Citación estilo Chicago

JL, Ordóñez, et al. The PARP Inhibitor Olaparib Enhances the Sensitivity of Ewing Sarcoma to Trabectedin. 2015.

Cita MLA

JL, Ordóñez, et al. The PARP Inhibitor Olaparib Enhances the Sensitivity of Ewing Sarcoma to Trabectedin. 2015.